Category Archives: Uncategorized

Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications

Demonstrates ongoing commitment to innovation in ophthalmics for Shire

P-321 is a Phase 2 investigational topical treatment for dry eye disease

Lexington, Massachusetts, and Durham, North Carolina, US – May 1, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) and Parion Sciences, Inc. today announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.

READ THE ENTIRE PRESS RELEASE HERE ►